HCPCS Level IIdrugActive
J9326
Telisotuzumab vedotin-tllv
BETOS: O1D
Effective: 2026-01-01
Description
Injection, telisotuzumab vedotin-tllv, 1 mg
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Emrelis
Manufacturer
AbbVie Inc.
HCPCS Dosage
1 MG
Billing Units
20.0000
2
NDC Products
asp
Pricing Source
Medicare Part B drugs are reimbursed at ASP + 6%. Pricing updates quarterly based on manufacturer-reported data.